Latest news with #ScottWhitaker
Miami Herald
07-07-2025
- Business
- Miami Herald
Housing and retail will replace Florida boat ramp parking. See what's planned
A six-story apartment complex with retail space has been tenatively approved to rise along the Manatee River on land that had been used for boat ramp parking. But the plans have set off backlash from residents. An online petition created in April 2021 garnered nearly 4,000 signatures opposing development of the property. In June, city of Palmetto leaders picked Mosaic Development's proposal to build the $53 million project. The development could be completed by the end of 2028, officials say. The proposed project would transform the 3.4-acre site on the corner of Eighth Avenue West and Riverside Drive into a six-story building with 155,652 square feet of apartments, 5,000 square feet of retail space and 5,000 square feet of amenities. 'The building is phenomenal. I really love the building, I love the concept,' Palmetto Commissioner Scott Whitaker said at a recent meeting. Amenities will include a deck with a pool and a two-level parking garage for residents and retail customers. The parking garage will be the base of the building and, overall, there will be about 368 parking spaces. What to know about the Manatee River complex Mosaic is no stranger to the 'urban style vertical living lifestyle' the company pitched for this project. The developer's portfolio includes projects like the recently completed Nine20 Manatee apartment building in downtown Bradenton and similar projects in Sarasota, Tampa and St. Petersburg. The residential portion of the project will consist of 152 one-and two-bedroom units 'to respond to the current marketplace demand of apartment living and help to create a critical mass of residents to support the growing popularity of the City of Palmetto,' according to the presentation. The average rent would be $2,177 per month. Controversial boat ramp parking Al three residents who spoke at a June Community Redevelopment Agency meeting on the proposal opposed the project. One of the common issues: the loss of boat parking space. Mosaic's plan includes 22 boat trailer parking spaces on the side of the building. 'The boat trailer parking, it could be cumbersome,' Commissioner Whitaker said at the meeting, adding that there is still room to navigate how boat trailer parking would be addressed. Palmetto apartment construction timeline The 3.4-acre parcel used to house a Shell gas station. After the CRA purchased the land for $1.1 million in 2012, the agency received funds from the U.S. Environmental Protection Agency and $300,000 in tax credits to clean up the site. On May 19, CRA board members ranked each developer's proposals based on 11 categories, and Mosaic's plan received the highest number of points. Then, on June 2, the board voted 4-1 in favor of Mosaic's plan to be selected for this project. Next comes seven weeks of negotiation before the plan comes back before the CRA board. City commissioners can use that period to talk to the developers individually to address any questions or concerns. After that, design could begin in September and last through May. The construction goal is to complete the project around August 2028, according to the presentation.
Yahoo
23-06-2025
- Business
- Yahoo
MedTech Europe urges EU to exclude devices, diagnostics from trade war
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. MedTech Europe urged policymakers last week to exempt medical technologies from any trade tariffs or export restrictions. The trade group said it is 'deeply concerned' that the European Commission's draft proposal for countermeasures to U.S. tariffs targets 'a broad range' of devices, diagnostics and components. MedTech Europe's intervention follows similar pleas from its U.S. counterpart AdvaMed, which has called for 'zero-for-zero' reciprocal tariffs on the trade of medtech products. The European Commission started a consultation into plans to impose tariffs on imports and restrictions on exports in May in response to actions taken by the U.S. MedTech Europe said the draft list of products 'includes over 800 trade codes related to medical technologies, covering finished goods as well as a variety of core components necessary for the functioning of medical devices and diagnostics.' Restrictions on the trade of the devices and components would disrupt supply chains and 'create ripple effects throughout the healthcare system,' MedTech Europe said. The trade group wants policymakers to know that companies may struggle to adapt their supply chains before patient care is affected. 'Replacing components is not a simple option,' MedTech Europe said. 'In some cases, no alternative exists. Where substitutes are possible, the process of revalidation is lengthy and resource-intensive to ensure the same high standards and safety are met. Delays to access to medical technologies ultimately affect patients.' MedTech Europe wants European policymakers to exempt medical technologies from any trade tariffs or export restrictions. The trade group also echoed AdvaMed's call for medical technologies to be covered by a zero-for-zero policy on trade between the U.S. and European Union. The U.S. imposed a 20% tariff on most goods imported from the EU but temporarily halved the rate to give negotiators time to reach a deal. The U.S. has threatened to impose a 50% tariff. Negotiators have until July 9 to reach an agreement or agree to extend talks. After that, the U.S. may reimpose tariffs at a higher rate, potentially triggering retaliatory measures from the EU that MedTech Europe wants to avoid. Recommended Reading AdvaMed CEO Scott Whitaker pleads for tariff relief in Senate hearing Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Why Boston Scientific Corporation (BSX) Is Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A surgeon examining a patient's brain in an operating room, paramedics nearby. Number of Hedge Fund Holders: 96 Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation. The company ranks fourth on our list of the top medical device stocks to invest in. On April 25, Barclays analyst Matt Miksic raised the firm's price target on Boston Scientific Corporation (NYSE:BSX) to $125 from $118, keeping an Overweight rating on the shares. The firm reasoned that solid results from ADVANTAGE-AF for using Farawave and Farapoint in persistent atrial fibrillation should allow FDA approval later this year. BTIG analyst Marie Thibault also maintained their bullish stance on the stock on April 23, giving it a buy rating based on its solid financial performance and promising outlook. Boston Scientific Corporation (NYSE:BSX) reported notable fiscal Q1 2025 revenue and EPS, surpassing both market expectations and its own guidance. The analyst attributed this success to higher-than-expected sales in electrophysiology and interventional cardiology. This holds especially true for the Farapulse franchise, which has positioned the company as a leader in the electrophysiology market. Boston Scientific Corporation (NYSE:BSX) has raised its 2025 revenue guidance, and the upcoming CFO transition is expected to maintain stability in leadership, reflecting confidence in its stable growth and sustained profitability. Overall, BSX ranks 4th on our list of the best medical device stocks to buy now. While we acknowledge the potential for BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BSX but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10-05-2025
- Business
- Yahoo
Why Stryker Corporation (SYK) Is Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A medical team wearing surgical masks and gloves carrying out a hip or knee joint replacement surgery with the help of surgical navigation systems. Number of Hedge Fund Holders: 70 Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services in Neurotechnology, Medical and Surgical, and Orthopedics and Spine. The company's medical devices and products include surgical navigation systems, surgical equipment, emergency medical equipment, endoscopic and communications systems, neurosurgical and neurovascular devices, Mako Robotic-Arm Assisted technology, and other products. Stryker Corporation (NYSE:SYK) holds around 13,000 global patents to shield its products from replication. On May 5, Wall Street analyst Lee Hambright from Bernstein revisited Stryker Corporation (NYSE:SYK). The analyst maintained a Buy rating on the stock with a $450.00 price target, based on the company's solid performance and future growth potential. Stryker Corporation's (NYSE:SYK) revenue increased 10.1% organically in fiscal Q1 2025, exceeding expectations by 3%. The growth was consistent across various segments and regions, pointing to a robust business model. The company has also effectively managed a $200 million tariff impact and adjusted its guidance to cover the Inari acquisition. Its Inari integration is on track, and future product launches are anticipated to drive further growth. According to the analyst, Stryker Corporation (NYSE:SYK) is set to experience continued above-market growth, supported by factors such as favorable demographics, the adoption of robotic-assisted surgery, and strong procedure volumes. Overall, SYK ranks 6th on our list of the best medical device stocks to buy now. While we acknowledge the potential for SYK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SYK but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10-05-2025
- Business
- Yahoo
Zimmer Biomet Holdings, Inc. (ZBH): Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Zimmer Biomet Holdings, Inc. (NYSE:ZBH) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A team of medical specialists discussing orthopaedic reconstructive surgery plans. Number of Hedge Fund Holders: 53 Zimmer Biomet Holdings, Inc. (NYSE:ZBH) designs, manufactures, and markets orthopedic reconstructive products. It also offers biologics, extremities, sports medicine, dental implants, trauma products, and related surgical products. The company leads the orthopedic sector with a 36% share in knee implants and a 23% share in hip implants. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also holds a competitive market advantage due to its regulatory expertise, as the development of medical implants requires a lengthy FDA approval process, creating a natural barrier to entry and limiting competition. On April 25, BTIG analyst Ryan Zimmerman maintained a Buy rating on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) and set a price target of $123.00. The analyst said that the company's recent strategic product introductions in the hip replacement sector position it well to regain market share. The company has launched innovative products such as the Z1 Triple Taper Stem, HAMMR, and OrthoGrid, which have received generally optimistic feedback from orthopedic surgeons. The products can improve Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) competitive position, supporting the Buy rating. Overall, ZBH ranks 11th on our list of the best medical device stocks to buy now. While we acknowledge the potential for ZBH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZBH but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
